Yvonne Heung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yvonne Heung has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Bruera
Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
6 shared publications - David Hui
Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4 shared publications Eduardo Bruera
Department of Palliative, Rehabilitation and Integrative Medicine (K.M.A., G.A.S., D.S.Z., Y.H., E.B., D.H.), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
4 shared publications- Akhila Reddy
Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3 shared publications Diane Liu
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
3 shared publicationsJanet Williams
Department of Palliative Care, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
3 shared publications
Latest Publications
- 23 September 2025
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 71 (1) , 60-69
Systematic Screening of Advanced Cancer Patients’ Curability Perception: A Longitudinal Analysis
- 23 September 2025
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 71 (1) , 60-69
Systematic Screening of Advanced Cancer Patients’ Curability Perception: A Longitudinal Analysis
- 24 June 2023
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 66 (3) , e431-e435
Opioid Prescription Denials by Community Pharmacies for Cancer-Related Pain: A Case Series
- 24 June 2023
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 66 (3) , e431-e435
Opioid Prescription Denials by Community Pharmacies for Cancer-Related Pain: A Case Series
- Open Access
Quality of End-of-Life Care during the COVID-19 Pandemic at a Comprehensive Cancer Center
To evaluate how the COVID-19 pandemic impacted the quality of end-of-life care for patients with advanced cancer, we compared a random sample of 250 inpatient deaths from 1 April 2019, to 31 July 2019, with 250 consecutive inpatient deaths from 1 April 2020, to 31 July 2020, at a comprehensive cancer center. Sociodemographic and clinical characteristics, the timing of palliative care referral, timing of do-not-resuscitate (DNR) orders, location of death, and pre-admission out-of-hospital DNR documentation were included. During the COVID-19 pandemic, DNR orders occurred earlier (2.9 vs. 1.7 days before death, p = 0.028), and palliative care referrals also occurred earlier (3.5 vs. 2.5 days before death, p = 0.041). During the pandemic, 36% of inpatient deaths occurred in the Intensive Care Unit (ICU) and 36% in the Palliative Care Unit, compared to 48 and 29%, respectively, before the pandemic (p = 0.001). Earlier DNR orders, earlier palliative care referrals, and fewer ICU deaths suggest an improvement in the quality of end-of-life care in response to the COVID-19 pandemic. These encouraging findings may have future implications for maintaining quality end-of-life care post-pandemic.
Open AccessQuality of End-of-Life Care during the COVID-19 Pandemic at a Comprehensive Cancer Center
To evaluate how the COVID-19 pandemic impacted the quality of end-of-life care for patients with advanced cancer, we compared a random sample of 250 inpatient deaths from 1 April 2019, to 31 July 2019, with 250 consecutive inpatient deaths from 1 April 2020, to 31 July 2020, at a comprehensive cancer center. Sociodemographic and clinical characteristics, the timing of palliative care referral, timing of do-not-resuscitate (DNR) orders, location of death, and pre-admission out-of-hospital DNR documentation were included. During the COVID-19 pandemic, DNR orders occurred earlier (2.9 vs. 1.7 days before death, p = 0.028), and palliative care referrals also occurred earlier (3.5 vs. 2.5 days before death, p = 0.041). During the pandemic, 36% of inpatient deaths occurred in the Intensive Care Unit (ICU) and 36% in the Palliative Care Unit, compared to 48 and 29%, respectively, before the pandemic (p = 0.001). Earlier DNR orders, earlier palliative care referrals, and fewer ICU deaths suggest an improvement in the quality of end-of-life care in response to the COVID-19 pandemic. These encouraging findings may have future implications for maintaining quality end-of-life care post-pandemic.
- 21 July 2022
- Published by Wiley in British Journal of Haematology
- Vol. 198 (6) , 974-982
Timing of referral to outpatient palliative care for patients with haematologic malignancies
Summary: Outpatient palliative‐care facilitates timely supportive‐care access; however, there is a paucity of studies on the timing of referral in the outpatient setting for patients with haematologic malignancy. We examined the trend in timing of outpatient palliative‐care referrals over a 10‐year period in patients with haematologic malignancies at our comprehensive cancer centre. We included consecutive patients with a diagnosis of haematologic malignancy who were seen at our outpatient palliative‐care clinic between 1 January 2010 and 31 December 2019. We collected data on patient characteristics, symptom burden and supportive‐care interventions at outpatient palliative‐care consultation. The primary outcome was time from outpatient palliative‐care consultation to death or last follow‐up. In all, 384 patients were referred by leukaemia (n = 143), lymphoma (n = 213), and stem cell transplant (n = 28) services. The median time from outpatient palliative‐care referral to death was 3.4 years (IQR 2.4–5.3) with a significant increase in both the number of referrals per year (p = 0.047) and the timing of referral between 2010 and 2019 (p = 0.001). Patients with haematologic malignancies were referred in a timely fashion to our outpatient palliative‐care clinic, with earlier and greater numbers of referrals over time.
- 21 July 2022
- Published by Wiley in British Journal of Haematology
- Vol. 198 (6) , 974-982
Timing of referral to outpatient palliative care for patients with haematologic malignancies
Summary: Outpatient palliative‐care facilitates timely supportive‐care access; however, there is a paucity of studies on the timing of referral in the outpatient setting for patients with haematologic malignancy. We examined the trend in timing of outpatient palliative‐care referrals over a 10‐year period in patients with haematologic malignancies at our comprehensive cancer centre. We included consecutive patients with a diagnosis of haematologic malignancy who were seen at our outpatient palliative‐care clinic between 1 January 2010 and 31 December 2019. We collected data on patient characteristics, symptom burden and supportive‐care interventions at outpatient palliative‐care consultation. The primary outcome was time from outpatient palliative‐care consultation to death or last follow‐up. In all, 384 patients were referred by leukaemia (n = 143), lymphoma (n = 213), and stem cell transplant (n = 28) services. The median time from outpatient palliative‐care referral to death was 3.4 years (IQR 2.4–5.3) with a significant increase in both the number of referrals per year (p = 0.047) and the timing of referral between 2010 and 2019 (p = 0.001). Patients with haematologic malignancies were referred in a timely fashion to our outpatient palliative‐care clinic, with earlier and greater numbers of referrals over time.
- 23 May 2022
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 32 (6) , 704-705
End-of-life care quality metrics in patients with cancer: challenges and opportunities
- 23 May 2022
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 32 (6) , 704-705
End-of-life care quality metrics in patients with cancer: challenges and opportunities
- Top Cited PapersOpen Access
Timely Palliative Care: Personalizing the Process of Referral
Timely palliative care is a systematic process to identify patients with high supportive care needs and to refer these individuals to specialist palliative care in a timely manner based on standardized referral criteria. It requires four components: (1) routine screening of supportive care needs at oncology clinics, (2) establishment of institution-specific consensual criteria for referral, (3) a system in place to trigger a referral when patients meet criteria, and (4) availability of outpatient palliative care resources to deliver personalized, timely patient-centered care aimed at improving patient and caregiver outcomes. In this review, we discuss the conceptual underpinnings, rationale, barriers and facilitators for timely palliative care referral. Timely palliative care provides a more rational use of the scarce palliative care resource and maximizes the impact on patients who are offered the intervention. Several sets of referral criteria have been proposed to date for outpatient palliative care referral. Studies examining the use of these referral criteria consistently found that timely palliative care can lead to a greater number of referrals and earlier palliative care access than routine referral. Implementation of timely palliative care at each institution requires oncology leadership support, adequate palliative care infrastructure, integration of electronic health record and customization of referral criteria.
Top Cited PapersOpen AccessTimely Palliative Care: Personalizing the Process of Referral
Timely palliative care is a systematic process to identify patients with high supportive care needs and to refer these individuals to specialist palliative care in a timely manner based on standardized referral criteria. It requires four components: (1) routine screening of supportive care needs at oncology clinics, (2) establishment of institution-specific consensual criteria for referral, (3) a system in place to trigger a referral when patients meet criteria, and (4) availability of outpatient palliative care resources to deliver personalized, timely patient-centered care aimed at improving patient and caregiver outcomes. In this review, we discuss the conceptual underpinnings, rationale, barriers and facilitators for timely palliative care referral. Timely palliative care provides a more rational use of the scarce palliative care resource and maximizes the impact on patients who are offered the intervention. Several sets of referral criteria have been proposed to date for outpatient palliative care referral. Studies examining the use of these referral criteria consistently found that timely palliative care can lead to a greater number of referrals and earlier palliative care access than routine referral. Implementation of timely palliative care at each institution requires oncology leadership support, adequate palliative care infrastructure, integration of electronic health record and customization of referral criteria.
- 1 February 2021
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 61 (2) , 358-363
Frequency and Characteristics of First-Time Palliative Care Referrals During the Last Day of Life
- 1 February 2021
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 61 (2) , 358-363
Frequency and Characteristics of First-Time Palliative Care Referrals During the Last Day of Life
- Open Access
Chronic Non-Malignant Pain in Patients with Cancer Seen at a Timely Outpatient Palliative Care Clinic
Palliative care is seeing cancer patients earlier in the disease trajectory with a multitude of chronic issues. Chronic non-malignant pain (CNMP) in cancer patients is under-studied. In this prospective study, we examined the prevalence and management of CNMP in cancer patients seen at our supportive care clinic for consultation. We systematically characterized each pain type with the Brief Pain Inventory (BPI) and documented current treatments. The attending physician made the pain diagnoses according to the International Association for the Study of Pain (IASP) task force classification. Among 200 patients (mean age 60 years, 69% metastatic disease, 1-year survival of 77%), the median number of pain diagnosis was 2 (IQR 1–2); 67 (34%, 95% CI 28–41%) had a diagnosis of CNMP; 133 (67%) had cancer-related pain; and 52 (26%) had treatment-related pain. In total, 12/31 (39%) patients with only CNMP and 21/36 (58%) patients with CNMP and other pain diagnoses were on opioids. There was a total of 94 CNMP diagnoses among 67 patients, including 37 (39%) osteoarthritis and 20 (21%) lower back pain; 30 (32%) were treated with opioids. In summary, CNMP was common in the timely palliative care setting and many patients were on opioids. Our findings highlight the need to develop clinical guidelines for CNMP in cancer patients to standardize its management.
Open AccessChronic Non-Malignant Pain in Patients with Cancer Seen at a Timely Outpatient Palliative Care Clinic
Palliative care is seeing cancer patients earlier in the disease trajectory with a multitude of chronic issues. Chronic non-malignant pain (CNMP) in cancer patients is under-studied. In this prospective study, we examined the prevalence and management of CNMP in cancer patients seen at our supportive care clinic for consultation. We systematically characterized each pain type with the Brief Pain Inventory (BPI) and documented current treatments. The attending physician made the pain diagnoses according to the International Association for the Study of Pain (IASP) task force classification. Among 200 patients (mean age 60 years, 69% metastatic disease, 1-year survival of 77%), the median number of pain diagnosis was 2 (IQR 1–2); 67 (34%, 95% CI 28–41%) had a diagnosis of CNMP; 133 (67%) had cancer-related pain; and 52 (26%) had treatment-related pain. In total, 12/31 (39%) patients with only CNMP and 21/36 (58%) patients with CNMP and other pain diagnoses were on opioids. There was a total of 94 CNMP diagnoses among 67 patients, including 37 (39%) osteoarthritis and 20 (21%) lower back pain; 30 (32%) were treated with opioids. In summary, CNMP was common in the timely palliative care setting and many patients were on opioids. Our findings highlight the need to develop clinical guidelines for CNMP in cancer patients to standardize its management.
- 1 September 2017
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 54 (3) , 280-288
The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients
- 1 September 2017
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 54 (3) , 280-288
The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients
- Open Access
The opioid rotation ratio of strong opioids to transdermal fentanyl in cancer patients
BACKGROUND: Transdermal fentanyl (TDF) is 1 of the most common opioids prescribed to patients with cancer. However, the accurate opioid rotation ratio (ORR) from other opioids to TDF is unknown, and various currently used methods result in wide variation of the ORR. The objective of this study was to determine the ORR of the oral morphine equivalent daily dose (MEDD) to the TDF dose when correcting for the MEDD of breakthrough opioids (the net MEDD) in cancer outpatients.METHODS: The records of 6790 consecutive patients were reviewed at the authors' supportive care center from 2010 to 2013 to identify those who underwent rotation from other opioids to TDF. Data regarding Edmonton Symptom Assessment Scale scores and MEDDs were collected for patients who returned for a follow‐up visit within 5 weeks. Linear regression analysis was used to estimate the ORR between the TDF dose and the net MEDD (the MEDD before opioid rotation [OR] minus the MEDD of the breakthrough opioid used along with TDF after OR).RESULTS: In total, 129 patients underwent OR from other opioids to TDF. The mean patient age was 56 years, 59% were men, and 88% had advanced cancer. Uncontrolled pain (80%) was the most frequent reason for OR. In 101 patients who underwent OR and had no worsening of pain at follow‐up, the median ORR from net MEDD to TDF (in mg per day) was 0.01 (range, −0.02 to 0.04), and the correlation coefficient of the TDF dose to the net MEDD was 0.77 (P < .0001). The ORR was not significantly impacted by body mass index or serum albumin. The ORR of 0.01 suggests that an MEDD of 100 mg is equivalent to 1 mg TDF daily or approximately 40 micrograms per hour of TDF (1000 micrograms/24 hours).CONCLUSIONS: The median ORR from MEDD to TDF in mg per day was 0.01. These results warrant further studies Cancer 2016;122:149–156. © 2015 American Cancer Society.
Open AccessThe opioid rotation ratio of strong opioids to transdermal fentanyl in cancer patients
BACKGROUND: Transdermal fentanyl (TDF) is 1 of the most common opioids prescribed to patients with cancer. However, the accurate opioid rotation ratio (ORR) from other opioids to TDF is unknown, and various currently used methods result in wide variation of the ORR. The objective of this study was to determine the ORR of the oral morphine equivalent daily dose (MEDD) to the TDF dose when correcting for the MEDD of breakthrough opioids (the net MEDD) in cancer outpatients.METHODS: The records of 6790 consecutive patients were reviewed at the authors' supportive care center from 2010 to 2013 to identify those who underwent rotation from other opioids to TDF. Data regarding Edmonton Symptom Assessment Scale scores and MEDDs were collected for patients who returned for a follow‐up visit within 5 weeks. Linear regression analysis was used to estimate the ORR between the TDF dose and the net MEDD (the MEDD before opioid rotation [OR] minus the MEDD of the breakthrough opioid used along with TDF after OR).RESULTS: In total, 129 patients underwent OR from other opioids to TDF. The mean patient age was 56 years, 59% were men, and 88% had advanced cancer. Uncontrolled pain (80%) was the most frequent reason for OR. In 101 patients who underwent OR and had no worsening of pain at follow‐up, the median ORR from net MEDD to TDF (in mg per day) was 0.01 (range, −0.02 to 0.04), and the correlation coefficient of the TDF dose to the net MEDD was 0.77 (P < .0001). The ORR was not significantly impacted by body mass index or serum albumin. The ORR of 0.01 suggests that an MEDD of 100 mg is equivalent to 1 mg TDF daily or approximately 40 micrograms per hour of TDF (1000 micrograms/24 hours).CONCLUSIONS: The median ORR from MEDD to TDF in mg per day was 0.01. These results warrant further studies Cancer 2016;122:149–156. © 2015 American Cancer Society.